2014
DOI: 10.1016/j.clon.2014.06.012
|View full text |Cite
|
Sign up to set email alerts
|

Patient-reported Outcomes and Health-related Quality of Life in Prostate Cancer Treated with a Single Fraction of High Dose Rate Brachytherapy Combined with Hypofractionated External Beam Radiotherapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
4
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 12 publications
(6 citation statements)
references
References 17 publications
2
4
0
Order By: Relevance
“…EPIC scores revealed mainly urinary baseline symptoms and showed transient changes in both domains over time similarly to literature findings [21,22,25]. Apart from a posttreatment decline, we noted a transient drop in GI QoL at bRFS: biochemical relapse-free survival (Phoenix definition: PSA nadir þ2 ng/ ml); LRFS: local relapse-free survival; DMFS: distant metastasis-free survival; DFS: disease-free survival; CSS: cancer-specific survival; OS: overall survival.…”
Section: Discussionsupporting
confidence: 87%
See 1 more Smart Citation
“…EPIC scores revealed mainly urinary baseline symptoms and showed transient changes in both domains over time similarly to literature findings [21,22,25]. Apart from a posttreatment decline, we noted a transient drop in GI QoL at bRFS: biochemical relapse-free survival (Phoenix definition: PSA nadir þ2 ng/ ml); LRFS: local relapse-free survival; DMFS: distant metastasis-free survival; DFS: disease-free survival; CSS: cancer-specific survival; OS: overall survival.…”
Section: Discussionsupporting
confidence: 87%
“…The dominant urinary symptom was dysuria as 17% of the patient developed transitory or permanently alpha blocker dependence. A low Gr.3 stricture rate of 2.6% was observed, which compares favorably to published results of 3-12% [1][2][3][4][5][6]22,23]. Despite the lack of clear correlation between dose-volume, non-dosimetry factors and stricture incidence [23,24], we believe that MR-based definition of membranous urethra might improve dose delivery and eventually decrease toxicity.…”
Section: Discussionsupporting
confidence: 79%
“…The primary objective was to evaluate the differences in HRQOL in the urinary domain between patients treated with LDRB and HDRB at 3 months using the Expanded Prostate Cancer Index Composite (EPIC)-26 short form 25 . The 3-month cut-off was chosen as the primary endpoint based on several studies revealing peak urinary symptoms at 3 to 6 months 26, 27, 28, 29, 30, 31, 32. The EPIC score is the most used HRQOL instrument; it has been validated in men with prostate cancer 33 and shown to be a robust tool with good psychometrics 34, 35, 36.…”
Section: Methodsmentioning
confidence: 99%
“…Studies evaluating QoL for patients treated with EBRT and HDRB were used as a surrogate for sample size calculation. Six studies investigating the effect of LDRB 26,29,32 and EBRT plus HDRB boost 27,30,31 on urinary function, using the urinary domain of the EPIC instrument as an outcome, were selected. Raw change scores from baseline were calculated and converted to effect sizes (d ), which were weighted using the study sample size and averaged by treatment modality (LDRB vs HDRB þ EBRT).…”
Section: Sample Sizementioning
confidence: 99%
“…76% for 24 months PRO data and 81% healthcare professional reported toxicity in prostate cancer patients. In comparison single centre studies in prostate cancer patients carried out up to two years following radiotherapy reported overall questionnaire completion rates of 50% [30], 85% in ProtecT [31], and 69% in CHHiP [32]. The REQUITE study also aimed at a low level of missing data, e.g.…”
Section: *5mentioning
confidence: 99%